Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for ARDX

Stock Name	Ardelyx Inc
Ticker	ARDX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US0396971071
LEI	549300F542QR4SXHCY32

Show aggregate ARDX holdings

News associated with ARDX

Implied XBI Analyst Target Price: $142: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-15 07:18:21
Ardelyx (NASDAQ:ARDX) CEO Michael Raab Sells 45,687 Shares of Stock: Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) CEO Michael Raab sold 45,687 shares of Ardelyx stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $5.93, for a total value of $270,923.91. Following the transaction, the chief executive officer owned 1,502,250 shares in the company, valued at $8,908,342.50. […] - 2025-08-26 05:24:52
Stock Traders Purchase Large Volume of Call Options on Ardelyx (NASDAQ:ARDX): Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 10,249 call options on the company. Thisisanincreaseofapproximately439% compared to the typical daily volume of 1,902 call options. Insider Activity In other Ardelyx news, CEO Michael Raab sold 46,817 shares of the stock in a […] - 2025-08-14 02:19:05
HC Wainwright Estimates Ardelyx’s Q3 Earnings (NASDAQ:ARDX): Ardelyx, Inc. (NASDAQ:ARDX – Free Report) – Equities researchers at HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for shares of Ardelyx in a note issued to investors on Tuesday, August 5th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will post earnings of ($0.07) per share for the […] - 2025-08-08 02:55:07
Mackenzie Financial Corp Grows Stock Position in Ardelyx, Inc. (NASDAQ:ARDX): Mackenzie Financial Corp boosted its position in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 6.4% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 149,158 shares of the biopharmaceutical company’s stock after purchasing an additional 9,025 shares during the period. Mackenzie Financial Corp’s holdings in Ardelyx were worth $732,000 as of its most recent […] - 2025-08-07 05:04:52
Ardelyx (NASDAQ:ARDX) Shares Gap Up After Better-Than-Expected Earnings: Shares of Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed at $4.39, but opened at $5.07. Ardelyx shares last traded at $5.06, with a volume of 3,144,528 shares traded. The biopharmaceutical company reported ($0.08) earnings per […] - 2025-08-07 02:13:02
Ardelyx (NASDAQ:ARDX) versus Esperion Therapeutics (NASDAQ:ESPR) Head to Head Review: Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) and Ardelyx (NASDAQ:ARDX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Institutional and Insider Ownership 47.4% of Esperion Therapeutics […] - 2025-08-01 04:30:46
Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 424,718 Ardelyx, Inc. (NASDAQ:ARDX): Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 424,718 shares of the biopharmaceutical company’s stock, valued at approximately $2,085,000. Universal Beteiligungs und Servicegesellschaft mbH owned […] - 2025-07-31 05:14:48
Brokerages Set Ardelyx, Inc. (NASDAQ:ARDX) PT at $10.89: Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) has earned an average rating of “Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the […] - 2025-07-30 04:24:53
Cwm LLC Buys 78,063 Shares of Ardelyx, Inc. (NASDAQ:ARDX): Cwm LLC lifted its stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 4,554.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,777 shares of the biopharmaceutical company’s stock after buying an additional 78,063 shares during the quarter. Cwm LLC’s holdings in Ardelyx were […] - 2025-07-25 05:09:08
Ardelyx, Inc. (NASDAQ:ARDX) Given Consensus Recommendation of “Buy” by Brokerages: Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) has earned an average recommendation of “Buy” from the ten brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-06-30 02:46:46
HC Wainwright Forecasts Ardelyx’s Q2 Earnings (NASDAQ:ARDX): Ardelyx, Inc. (NASDAQ:ARDX – Free Report) – HC Wainwright issued their Q2 2025 earnings per share estimates for Ardelyx in a research note issued to investors on Wednesday, June 18th. HC Wainwright analyst M. Caufield anticipates that the biopharmaceutical company will post earnings per share of ($0.14) for the quarter. HC Wainwright has a “Buy” […] - 2025-06-24 02:24:51
World Equity Group Inc. Acquires New Shares in Ardelyx, Inc. (NASDAQ:ARDX): World Equity Group Inc. bought a new position in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 17,400 shares of the biopharmaceutical company’s stock, valued at approximately $85,000. Other large investors have also bought and sold […] - 2025-06-23 05:36:49
SG Americas Securities LLC Buys 111,457 Shares of Ardelyx, Inc. (NASDAQ:ARDX): SG Americas Securities LLC boosted its stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 203.1% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 166,343 shares of the biopharmaceutical company’s stock after buying an additional 111,457 shares during the quarter. SG Americas Securities LLC’s holdings in Ardelyx were worth $817,000 as of its […] - 2025-06-20 05:12:54
Ardelyx (NASDAQ:ARDX) Now Covered by HC Wainwright: Investment analysts at HC Wainwright initiated coverage on shares of Ardelyx (NASDAQ:ARDX – Get Free Report) in a research note issued on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 177.01% from the stock’s previous […] - 2025-06-20 02:15:21
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Recommendation of “Moderate Buy” by Analysts: Shares of Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on […] - 2025-06-05 02:48:52
Mackenzie Financial Corp Purchases 101,841 Shares of Ardelyx, Inc. (NASDAQ:ARDX): Mackenzie Financial Corp raised its position in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 266.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 140,133 shares of the biopharmaceutical company’s stock after acquiring an additional 101,841 shares during the period. Mackenzie Financial Corp’s holdings in Ardelyx were worth $710,000 as of its most recent […] - 2025-06-02 05:49:04
Two Sigma Advisers LP Increases Position in Ardelyx, Inc. (NASDAQ:ARDX): Two Sigma Advisers LP grew its stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 206.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 593,700 shares of the biopharmaceutical company’s stock after acquiring an additional 400,100 shares during the quarter. Two Sigma Advisers […] - 2025-05-28 06:23:01
ProShare Advisors LLC Acquires 19,643 Shares of Ardelyx, Inc. (NASDAQ:ARDX): ProShare Advisors LLC lifted its holdings in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 34.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,469 shares of the biopharmaceutical company’s stock after buying an additional 19,643 shares during the period. ProShare […] - 2025-05-28 04:54:54
Ardelyx, Inc. (NASDAQ:ARDX) Shares Purchased by Two Sigma Investments LP: Two Sigma Investments LP grew its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 16.0% in the 4th quarter, Holdings Channel reports. The fund owned 1,141,777 shares of the biopharmaceutical company’s stock after acquiring an additional 157,416 shares during the period. Two Sigma Investments LP’s holdings in Ardelyx were worth $5,789,000 as […] - 2025-05-27 05:29:06
Analysts Set Ardelyx, Inc. (NASDAQ:ARDX) Target Price at $10.39: Shares of Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating […] - 2025-05-14 02:34:50
126,530 Shares in Ardelyx, Inc. (NASDAQ:ARDX) Acquired by Tudor Investment Corp ET AL: Tudor Investment Corp ET AL purchased a new stake in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 126,530 shares of the biopharmaceutical company’s stock, valued at approximately $642,000. Tudor Investment Corp ET AL owned about […] - 2025-05-08 06:12:50
First Trust Advisors LP Sells 305,383 Shares of Ardelyx, Inc. (NASDAQ:ARDX): First Trust Advisors LP lowered its stake in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 53.2% during the fourth quarter, Holdings Channel reports. The fund owned 268,924 shares of the biopharmaceutical company’s stock after selling 305,383 shares during the period. First Trust Advisors LP’s holdings in Ardelyx were worth $1,363,000 at the end […] - 2025-05-07 05:15:07
Ardelyx (NASDAQ:ARDX) Stock Price Down 8.4% Following Insider Selling: Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) shares dropped 8.4% during trading on Monday after an insider sold shares in the company. The stock traded as low as $3.89 and last traded at $3.79. Approximately 3,550,524 shares were traded during trading, a decline of 18% from the average daily volume of 4,347,468 shares. The stock […] - 2025-05-07 02:23:00
Raymond James Financial Inc. Takes Position in Ardelyx, Inc. (NASDAQ:ARDX): Raymond James Financial Inc. bought a new stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) in the 4th quarter, HoldingsChannel.com reports. The firm bought 183,490 shares of the biopharmaceutical company’s stock, valued at approximately $930,000. Several other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings […] - 2025-05-06 04:36:46
Ardelyx (NASDAQ:ARDX) Lowered to “Sell” Rating by StockNews.com: StockNews.com cut shares of Ardelyx (NASDAQ:ARDX – Free Report) from a hold rating to a sell rating in a report released on Monday. Other analysts have also recently issued research reports about the stock. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $11.00 price target on shares of Ardelyx in a research note […] - 2025-05-06 02:56:44
Wedbush Estimates Ardelyx’s Q4 Earnings (NASDAQ:ARDX): Ardelyx, Inc. (NASDAQ:ARDX – Free Report) – Equities research analysts at Wedbush boosted their Q4 2025 earnings estimates for Ardelyx in a research report issued on Friday, May 2nd. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of $0.01 for the quarter, up from their previous estimate of […] - 2025-05-05 04:24:50
Barclays PLC Sells 14,671 Shares of Ardelyx, Inc. (NASDAQ:ARDX): Barclays PLC reduced its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 532,654 shares of the biopharmaceutical company’s stock after selling 14,671 shares during the period. Barclays PLC’s holdings […] - 2025-05-01 05:12:53
LPL Financial LLC Has $704,000 Position in Ardelyx, Inc. (NASDAQ:ARDX): LPL Financial LLC lessened its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 29.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 138,804 shares of the biopharmaceutical company’s stock after selling 58,562 shares during the period. LPL Financial LLC’s holdings in Ardelyx were worth […] - 2025-04-23 04:18:48
CreativeOne Wealth LLC Takes $274,000 Position in Ardelyx, Inc. (NASDAQ:ARDX): CreativeOne Wealth LLC purchased a new position in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 53,993 shares of the biopharmaceutical company’s stock, valued at approximately $274,000. Other institutional investors and hedge funds have also […] - 2025-04-21 05:13:01

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ARDX holdings

Date	Number of ARDX Shares Held	Base Market Value of ARDX Shares	Local Market Value of ARDX Shares	Change in ARDX Shares Held	Change in ARDX Base Value	Current Price per ARDX Share Held	Previous Price per ARDX Share Held
2025-09-26 (Friday)	24,110	USD 133,569	USD 133,569
2025-09-25 (Thursday)	24,110	USD 143,696	USD 143,696	0	USD -4,581	USD 5.96002	USD 6.15002
2025-09-24 (Wednesday)	24,110	USD 148,277	USD 148,277
2025-09-17 (Wednesday)	23,954	USD 148,275	USD 148,275	0	USD -5,510	USD 6.18999	USD 6.42001
2025-09-16 (Tuesday)	23,954	USD 153,785	USD 153,785
2025-09-12 (Friday)	23,798	USD 157,305	USD 157,305
2025-09-11 (Thursday)	23,798	USD 158,971	USD 158,971

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ARDX by Blackrock for IE00B3VWM098

Show aggregate share trades of ARDX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -78 6.110* 4.84 Profit of 378 on sale
2025-07-31 BUY 234 4.240* 4.84
2025-06-30 SELL -156 3.920* 4.90 Profit of 764 on sale
2025-06-25 SELL -78 3.630* 4.92 Profit of 384 on sale
2025-06-20 SELL -156 3.560* 4.95 Profit of 773 on sale
2025-05-23 BUY 78 3.970* 5.15
2025-05-19 SELL -78 4.060* 5.19 Profit of 405 on sale
2025-05-15 SELL -234 3.380* 5.21 Profit of 1,220 on sale
2025-05-12 SELL -78 3.530* 5.26 Profit of 410 on sale
2025-05-09 SELL -78 3.620* 5.28 Profit of 412 on sale
2025-04-30 SELL -78 5.505* 5.34 Profit of 417 on sale
2025-04-24 SELL -156 5.020* 5.35 Profit of 834 on sale
2025-04-17 SELL -78 4.815* 5.38 Profit of 419 on sale
2025-04-15 SELL -234 4.640* 5.39 Profit of 1,262 on sale
2025-04-14 SELL -234 4.570* 5.40 Profit of 1,264 on sale
2025-04-09 SELL -312 4.500* 5.43 Profit of 1,696 on sale
2025-04-07 SELL -546 4.450* 5.46 Profit of 2,981 on sale
2025-04-04 SELL -780 4.550* 5.47 Profit of 4,266 on sale
2025-03-31 BUY 78 4.910* 5.49
2025-03-19 SELL -156 5.370* 5.52 Profit of 862 on sale
2025-03-14 SELL -468 5.470* 5.53 Profit of 2,587 on sale
2025-03-13 SELL -156 5.420* 5.53 Profit of 863 on sale
2025-03-12 SELL -2,652 5.440* 5.53 Profit of 14,669 on sale
2025-03-07 SELL -156 5.300* 5.54 Profit of 864 on sale
2025-03-06 SELL -234 5.320* 5.54 Profit of 1,297 on sale
2025-03-03 SELL -78 5.080* 5.55 Profit of 433 on sale
2025-02-28 SELL -468 5.360* 5.55 Profit of 2,600 on sale
2025-02-26 SELL -78 5.100* 5.57 Profit of 434 on sale
2025-02-25 SELL -234 5.180* 5.57 Profit of 1,304 on sale
2025-02-18 BUY 390 6.420* 5.54
2025-02-13 BUY 78 5.660* 5.53
2025-02-12 BUY 78 5.450* 5.53
2025-02-11 BUY 234 5.520* 5.53
2025-02-06 BUY 702 5.670* 5.53
2025-01-27 BUY 78 5.470* 5.55
2024-12-30 BUY 390 5.250* 5.57
2024-12-06 BUY 312 5.720* 5.59
2024-12-05 BUY 78 5.500* 5.59
2024-12-04 BUY 390 5.580* 5.59
2024-11-29 BUY 390 5.670* 5.59
2024-11-27 BUY 312 5.690* 5.59
2024-11-26 BUY 78 5.350* 5.60
2024-11-21 BUY 390 5.120* 5.65
2024-11-20 BUY 234 4.920* 5.70
2024-11-18 BUY 936 4.960* 5.80
2024-11-12 BUY 624 4.590* 5.88
2024-11-08 BUY 390 5.070* 5.94
2024-11-07 BUY 1,170 6.380* 5.90
2024-11-06 BUY 156 6.490* 5.85
2024-10-31 BUY 78 5.870* 5.83
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-78	6.110*	4.84 Profit of 378 on sale
2025-07-31	BUY	234	4.240*	4.84
2025-06-30	SELL	-156	3.920*	4.90 Profit of 764 on sale
2025-06-25	SELL	-78	3.630*	4.92 Profit of 384 on sale
2025-06-20	SELL	-156	3.560*	4.95 Profit of 773 on sale
2025-05-23	BUY	78	3.970*	5.15
2025-05-19	SELL	-78	4.060*	5.19 Profit of 405 on sale
2025-05-15	SELL	-234	3.380*	5.21 Profit of 1,220 on sale
2025-05-12	SELL	-78	3.530*	5.26 Profit of 410 on sale
2025-05-09	SELL	-78	3.620*	5.28 Profit of 412 on sale
2025-04-30	SELL	-78	5.505*	5.34 Profit of 417 on sale
2025-04-24	SELL	-156	5.020*	5.35 Profit of 834 on sale
2025-04-17	SELL	-78	4.815*	5.38 Profit of 419 on sale
2025-04-15	SELL	-234	4.640*	5.39 Profit of 1,262 on sale
2025-04-14	SELL	-234	4.570*	5.40 Profit of 1,264 on sale
2025-04-09	SELL	-312	4.500*	5.43 Profit of 1,696 on sale
2025-04-07	SELL	-546	4.450*	5.46 Profit of 2,981 on sale
2025-04-04	SELL	-780	4.550*	5.47 Profit of 4,266 on sale
2025-03-31	BUY	78	4.910*	5.49
2025-03-19	SELL	-156	5.370*	5.52 Profit of 862 on sale
2025-03-14	SELL	-468	5.470*	5.53 Profit of 2,587 on sale
2025-03-13	SELL	-156	5.420*	5.53 Profit of 863 on sale
2025-03-12	SELL	-2,652	5.440*	5.53 Profit of 14,669 on sale
2025-03-07	SELL	-156	5.300*	5.54 Profit of 864 on sale
2025-03-06	SELL	-234	5.320*	5.54 Profit of 1,297 on sale
2025-03-03	SELL	-78	5.080*	5.55 Profit of 433 on sale
2025-02-28	SELL	-468	5.360*	5.55 Profit of 2,600 on sale
2025-02-26	SELL	-78	5.100*	5.57 Profit of 434 on sale
2025-02-25	SELL	-234	5.180*	5.57 Profit of 1,304 on sale
2025-02-18	BUY	390	6.420*	5.54
2025-02-13	BUY	78	5.660*	5.53
2025-02-12	BUY	78	5.450*	5.53
2025-02-11	BUY	234	5.520*	5.53
2025-02-06	BUY	702	5.670*	5.53
2025-01-27	BUY	78	5.470*	5.55
2024-12-30	BUY	390	5.250*	5.57
2024-12-06	BUY	312	5.720*	5.59
2024-12-05	BUY	78	5.500*	5.59
2024-12-04	BUY	390	5.580*	5.59
2024-11-29	BUY	390	5.670*	5.59
2024-11-27	BUY	312	5.690*	5.59
2024-11-26	BUY	78	5.350*	5.60
2024-11-21	BUY	390	5.120*	5.65
2024-11-20	BUY	234	4.920*	5.70
2024-11-18	BUY	936	4.960*	5.80
2024-11-12	BUY	624	4.590*	5.88
2024-11-08	BUY	390	5.070*	5.94
2024-11-07	BUY	1,170	6.380*	5.90
2024-11-06	BUY	156	6.490*	5.85
2024-10-31	BUY	78	5.870*	5.83

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ARDX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	243,508	0	910,711	26.7%
2025-09-18	163,031	0	1,218,555	13.4%
2025-09-17	192,417	720	1,041,651	18.5%
2025-09-16	343,491	0	1,238,006	27.7%
2025-09-15	380,887	0	1,269,373	30.0%
2025-09-12	277,172	0	972,855	28.5%
2025-09-11	424,041	0	1,606,781	26.4%
2025-09-10	296,230	5,649	1,113,032	26.6%
2025-09-09	493,052	5,291	1,532,358	32.2%
2025-09-08	299,640	11,550	1,323,257	22.6%
2025-09-05	307,219	213	1,359,359	22.6%
2025-09-04	606,219	36,348	2,075,195	29.2%
2025-09-03	442,722	150	1,420,813	31.2%
2025-09-02	318,192	0	1,214,569	26.2%
2025-08-29	309,445	9,669	919,460	33.7%
2025-08-28	259,292	8,897	1,103,318	23.5%
2025-08-27	230,239	0	948,601	24.3%
2025-08-26	184,495	0	671,539	27.5%
2025-08-25	397,817	0	1,470,035	27.1%
2025-08-22	478,383	5,489	1,695,410	28.2%
2025-08-21	675,006	362,175	1,442,464	46.8%
2025-08-20	583,352	0	2,375,098	24.6%
2025-08-19	423,390	1,328	2,214,575	19.1%
2025-08-18	484,834	3,364	1,706,452	28.4%
2025-08-15	572,498	0	1,631,528	35.1%
2025-08-14	556,834	10,819	1,480,831	37.6%
2025-08-13	679,817	843	2,318,345	29.3%
2025-08-12	380,017	7,562	1,317,598	28.8%
2025-08-11	430,003	5,376	1,522,233	28.2%
2025-08-08	468,950	10,983	1,686,084	27.8%
2025-08-07	421,784	18,614	1,650,966	25.5%
2025-08-06	1,253,548	30,666	3,221,804	38.9%
2025-08-05	2,037,559	79,313	6,276,533	32.5%
2025-08-04	628,201	15,312	1,926,120	32.6%
2025-08-01	798,743	0	2,062,178	38.7%
2025-07-31	643,690	18,644	1,783,990	36.1%
2025-07-30	557,517	200	1,728,168	32.3%
2025-07-29	430,221	4,987	1,159,629	37.1%
2025-07-28	631,589	19,820	1,661,568	38.0%
2025-07-25	385,533	0	1,615,633	23.9%
2025-07-24	356,853	28,203	1,105,683	32.3%
2025-07-23	326,121	0	1,262,775	25.8%
2025-07-22	262,693	0	951,207	27.6%
2025-07-21	767,966	6,596	1,891,552	40.6%
2025-07-18	509,887	181	1,254,817	40.6%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE